PSYB:CC News and Press, Psybio Therapeutics Corp. From 04/25/22

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences , the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Co...

PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022 Canada NewsWire OXFORD, Ohio and COCONUT CREEK, Fla. , April 19, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF)  ("PsyBio" or the "Company"), an...

PsyBio Therapeutics Initiates Clinical Trial Site Selection Process Canada NewsWire PsyBio Therapeutics is developing a network of highly qualified, local principal investigators to recruit and conduct upcoming clinical trials OXFORD, Ohio and COCONUT CRE...

PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022 Canada NewsWire OXFORD, Ohio and COCONUT CREEK, Fla. , March 23, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF)  (" Ps...

PsyBio Announced The Acquisition of Everest Pharma Ltd. PsyBio has announced that it will acquire Everest Pharm Ltd, a company based in Lesotho, Africa. The acquisition gives PsyBio an operating license for psychedelic compounds outside North America for activities ranging from cultivation thr...

PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment Strategy Canada NewsWire PsyBio Therapeutics to Make Significant Environmental, Social, and Governance (ESG) ...